Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

WEDNESDAY, April 16, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved a self-injection version of ...

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung ...

for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

This study was supported by Amgen. Nowak reported relationships with the National Institutes of Health, Genentech, Alexion Pharmaceuticals, Argenx, Annexon Biosciences, Ra Pharmaceuticals (now UCB), ...

Last week­end, re­searchers gath­ered in San Diego for the Amer­i­can Acad­e­my of Neu­rol­o­gy’s an­nu­al meet­ing to dis­cuss the lat­est ad­vance­ments and clin­i­cal tri­ ...

These two Amgen drugs—sharing the active ingredient denosumab—are used to treat various bone-related conditions, including osteoporosis and bone complications in cancer patients. Together ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

Amgen is also evaluating Uplizna for treating generalized myasthenia gravis, another immune-mediated disease. Bristol Myers Squibb announced that it has obtained FDA approval for the label ...

Soliris contributed $2.58 billion in global revenues to AZ last year, a 14% drop on the prior year, of which just over $1.4 billion came from the US market. It has been overtaken by stablemate ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Stocks like Pfizer, Amgen, Johnson & Johnson, and Eli Lilly & Co. were among others which opened lower after the US stock market opened on Wednesday. Pfizer Inc. shares are currently trading 2.56 ...